PepGen’s Q3 GAAP EPS of -$0.79 beats estimates by $0.21. Company has $195.8 million in cash and cash equivalents as of September 30, 2022.

Trending News 🌥️

Pepgen Inc Stock Fair Value – PEPGEN ($NASDAQ:PEPG): PepGen Inc. is a pharmaceutical company that focuses on the development and commercialization of therapeutic peptides. The company’s Q3 GAAP EPS of -$0.79 beats estimates by $0.21. PepGen’s strong performance in Q3 can be attributed to the company’s focus on developing innovative therapeutic peptides.

Earnings

The company’s net income for the quarter was $0.0 million, or $0.00 per share, compared to a net loss of $50.8 million, or $0.79 per share, for the same period last year.

Share Price

PepGen Inc. reported better-than-expected earnings for the third quarter on Thursday, sending shares soaring by 12.9% in premarket trading. PepGen’s strong earnings report was driven by solid performance in its core businesses. The company’s results were also boosted by favorable tax and currency effects.

Looking ahead, PepGen expects to continue its strong performance in the fourth quarter and beyond. The company is well-positioned to capitalize on favorable market trends and continue its growth trajectory.

VI Analysis – Pepgen Inc Stock Fair Value

Company fundamentals are important indicators of a company’s long-term potential. The VI app makes it easy to analyze a company’s PEPGEN INC fundamentals. The fair value of PEPGEN INC shares is around $10.7, calculated by VI Line. Now PEPGEN INC stock is traded at $12.5, a fair price overvalued by 17%.

VI Peers

The company’s focus is on the development of first-in-class small molecule drugs that target the epigenome. PepGen’s most advanced product candidate is PEP-3074, a small molecule inhibitor of DOT1L, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and mixed lineage leukemia (MLL). The company is also developing PEP-3102, a small molecule inhibitor of BET bromodomain proteins, which is in Phase I clinical trials for the treatment of advanced solid tumors. PepGen’s competitors include Autolus Therapeutics PLC, Aldeyra Therapeutics Inc, Cyclerion Therapeutics Inc, and others.

– Autolus Therapeutics PLC ($NASDAQ:AUTL)

Autolus Therapeutics PLC is a clinical-stage biopharmaceutical company, which engages in the research and development of programmed T cell therapies for the treatment of cancer. It operates through the following segments: Autologous and Allogeneic. The Autologous segment develops products derived from a patient’s own cells. The Allogeneic segment focuses on developing off-the-shelf product candidates, which are designed to be administered to any patient without the need for pre-treatment. The company was founded by Christian B. Behrens and Martin Pule on March 3, 2014 and is headquartered in London, the United Kingdom.

– Aldeyra Therapeutics Inc ($NASDAQ:ALDX)

Aldeyra Therapeutics is a biopharmaceutical company focused on the development and commercialization of products to treat diseases related to inflammation, injury, and dysfunction of the eye. The company’s lead product candidate, Reproxalap, is in Phase 3 clinical development for the treatment of non-infectious anterior uveitis, allergic conjunctivitis, and dry eye disease. Aldeyra reported a loss of $16.4 million in 2020, and its market cap was $320.8 million as of 2022. The company’s return on equity was -22.1%.

– Cyclerion Therapeutics Inc ($NASDAQ:CYCN)

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat patients with serious and neglected diseases. The company’s lead product candidate, linaclotide, is in development for the treatment of rare gastrointestinal disorders. Cyclerion Therapeutics Inc has a market cap of 20.67M as of 2022, a Return on Equity of -145.28%.

Summary

PepGen Inc. is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for the treatment of cancer and other diseases. The company’s lead product candidate, PEP-12, is a targeted cancer immunotherapy that is currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors. PepGen’s strong financial position, with $195.8 million in cash and cash equivalents as of September 30, 2022, gives the company the resources it needs to continue advancing its clinical programs. Given the potential of PEP-12 and the company’s sound financials, PepGen could be an attractive investment opportunity for investors seeking exposure to the biotech sector.